Sci Rep (2018) 8:8283
Table A : GLP-1RAs versus other glucose-lowering agents: key specific features that impact treatment choice Given that there are few head-to-head studies comparing glucose-lowering effects between different drug classes, and the difficulty involved in performing cross-study comparisons due to different patient characteristics and baseline HbA 1c levels, there is widespread consensus that GLP-1RAs are more efficacious at lowering blood glucose than either DPP-IVs or SGLT-2 inhibitors
But as with any compound, especially one not yet clinically approved for human use , its safety depends on: The quality of the peptide The accuracy of the dose and administration The duration and purpose of your use Your individual health profile and risk tolerance While BPC-157 exhibits an extraordinary safety profile in animals, its long-term safety in humans remains to be fully established. Sikiric, P
d) Anti-tumor activity in mice [11] Polyethylene glycol (PEG) is frequently used (e.g., in Trodelvy and Zynlonta) to enhance solubility and stealth
Youre not aloneand thats where carnitine might come into play
While individual patterns vary based on personal fat distribution and receptor density, users commonly report improvements in areas that had not responded adequately to diet and exercise alone